From RNA interference technology to effective therapy: How far have we come and how far to go?

Therapeutic Delivery

Volumn 2, Issue 11, 2011, Pages 1395-1406

  Keaney, James ^a   Campbell, Matthew ^a   Humphries, Peter ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 5; MICRORNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SUNITINIB; TANESPIMYCIN;

ADVANCED CANCER; BLOOD BRAIN BARRIER; BLOOD RETINA BARRIER; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG STABILITY; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE TECHNOLOGY; GENE THERAPY; HUMAN; IMMUNOREACTIVITY; LIPOSOMAL DELIVERY; LIVER CELL CARCINOMA; LIVER METASTASIS; LOW DRUG DOSE; MELANOMA; METASTASIS; NANOENCAPSULATION; NANOPHARMACEUTICS; NEUROLOGIC DISEASE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIMARY TUMOR; PRIORITY JOURNAL; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RNA INTERFERENCE; SOLID TUMOR; SUBRETINAL NEOVASCULARIZATION; VIRAL GENE DELIVERY SYSTEM;

EID: 80054953659     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.109     Document Type: Review

References (71)

1. Fire A, Xu S, Montgomery MK et al. Potent and specific genetic interference by double stranded RNA in Caenorhabditis. Elegans Nat. 391, 806-811 (1998). The seminal paper detailing the phenomenon of RNAi in Caenorhabditis elegans.
2. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 8, 173-184 (2007).
3. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498 (2001). Exogenous siRNA achieves efficient sequence-specific gene suppression in mammalian cells.
4. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8, 129-138 (2009).
5. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA. RNA interference in adult mice. Nature. 418, 38-39 (2002).
6. Wang J, Lu Z, Wientjes G, Au JLS. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 12(4), 492-503 (2010).
7. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 136(4), 642-655 (2009).
8. Grimm D. Small silencing RNAs: state-of-the-art. Adv. Drug Deliv. Rev. 61, 672-703 (2009).
9. Martinez J, Patkaniowska A, Urlaub H, Lührmann R, Tuschl T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110, 565-574 (2002).
10. Liu J, Carmell MA, Rivas FV et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 305, 1437-1441 (2004).
11. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol. Cell 15, 185-197 (2004).
12. Wadhwa R, Kaul SC, Miyagishi M, Taira K. Know how of RNA interference and its applications in research and therapy. Mutation Res. 567, 71-84 (2004).
13. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550-553 (2002). Provides the first description of constructing short-hairpin RNA for sustained RNAi activity.
14. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 11, 50-55 (2005).
15. Grzelinski M, Urban-Klein B, Martens T et al. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum. Gene Ther. 17, 751-766 (2006).
16. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J. Cont. Rel.129, 107-116 (2008).
17. Pecot CV, Calin GA, Coleman GA, Lopez-Berestein G, Sood AK. RNA interference in the clinic: challenges and future directions. Nat. Rev. Cancer 11, 59-67 (2011).
18. Campbell M, Ozaki E, Humphries P. Systemic delivery of therapeutics to neuronal tissues: a barrier modulation approach. Exp. Opin. Drug Deliv. 7(7), 859-869 (2010).
19. Zimmerman TS, Lee AC, Akinc A. RNAi-mediated gene silencing in non-human primates. Nature 441, 111-114 (2006).
20. Alnylam pharmaceuticals. Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. In: American Society of Clinical Oncology Meeting. Chicago IL, USA, 4-8 June (2011).
21. Petrocca F, Lieberman J. Promise and challenge of RNA interference-based therapy for cancer. J. Clin. Oncol. 29, 747-754 (2009).
22. Akinc A, Querbes W, De S. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357-1364 (2010).
23. Silence therapeutics. First in-human Phase I study of Atu027, a liposomal small interfering RNA formulation, targeting protein kinase N3 (PKN3) in patients with advanced solid tumors. Presented at: American Society of Clinical Oncology Meeting. Chicago IL, USA, 4-8 June (2011).
24. Semple SC, Akinc A, Chen J et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotech. 28, 172-176 (2010).
25. Dokka S, Toledo D, Shi X, Castranova V, Rojanasakul Y. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm. Res. 17, 521-525 (2000).
26. Akinc A, Thomas M, Klibanov AM, Langer R. Exploring polyethylenimine- mediated DNA transfection and the proton sponge hypothesis. J. Gene Med. 7(5), 657-663 (2004).
27. Campbell M, Nguyen A, Kiang AS et al. An experimental platform for systemic drug delivery to the retina. PNAS 106(42), 17817-17822 (2009). Outlines the use of RNAi-mediated barrier modulation technology pertinent to the blood-retina barrier and delivery of low-molecular weight compounds to treat retinal disorders.
28. Heidel JD, Yu Z, Yi-Ching Leu J et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. PNAS 104(14), 5715-5721 (2007).
29. Davis ME, Zuckerman JE, Hang J et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1071 (2010). Provides the first report of siRNA delivery in humans using tissue-specific conjugated nanoparticles.
30. Hare P. RNA interference in three humans. Nat. Biotech. 28(4), 335 (2010).
31. Zhang K, Wang Q, Xie Y et al. Receptor-mediated delivery of siRNAs by tethered nucleic acid base-paired interactions. RNA 14(30), 577-583.
32. Tam LCS, Kiang AS, Kennan A et al. Therapeutic benefit derived from RNAi-mediated ablation of IMPDH1 transcripts in a murine model of autosomal dominant retinitis pigmentosa (RP10). Hum. Mol. Gen. 17(14), 2084-2100.
33. Campbell M, Humphries MM, Kiang AS et al. Systemic low-molecular weight drug delivery to pre-selected neuronal regions. EMBO Mol. Med. 3, 1-11 (2011). Describes the novel procedure for controlled and reversible blood-brain barrier and blood-retina barrier modulation using RNAi technology coupled with an adeno-associated virus vector delivery vehicle.
34. Castanotto D, Rossi JJ. The promises and pitfalls of RNA interference-based therapeutics. Nature 457, 426-433 (2009).
35. Kleinman ME, Yamada K, Takeda A et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452, 591-597 (2008).
36. Robbins M, Judge A, Liang L et al. 2′-O-methyl-modified RNAs act as TLR7 antagonists. Mol. Ther. 15(9), 1663-1669 (2007).
37. Poeck H, Besch R, Maihofer C et al. 5′-triphosphate siRNA: turning gene silencing and Rig-1 activation against melanoma. Nat. Med. 14, 1256-1263 (2008).
38. Jackson AL, Bartz SR, Schelter J et al. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotech. 21, 625-637 (2003).
39. Jackson AL, Burchard J, Schelter J et al. Widespread siRNA 'off-target' transcript silencing mediated by seed region sequence complementarity. RNA 12, 1179-1187 (2006).
40. Persengiev S, Zhu X, Green M. Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 10, 12-18 (2004).
41. Scacheri PC, Rozenblatt-Rosen O, Caplen NJ et al. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. PNAS 101(7), 1892-1897 (2004).
42. Jackson AL, Burchard J, Leake D et al. Position-specific chemical modification of siRNAs reduces 'off-target' transcript silencing. RNA 12(7), 1197-1205 (2006).
43. Bramsen JB, Laursen MB, Nielsen AF et al. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res. 37(9), 2867-2881 (2009).
44. Bramsen JB, Pakula MM, Hansen TB et al. A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Res. 38(17), 5761-5773 (2010).
45. Laursen MB, Pakula MM, Gao S et al. Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo. Mol. Biosys. 6, 862-870 (2010).
46. Vaish N, Chen F, Seth S et al. Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs. Nucleic Acids Res. 39(5), 1823-1832 (2011).
47. Grimm D, Streetz KL, Jopling CL et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nat. Lett. 441, 537-541 (2006). First report of RNAi-related toxic side effects as a result of RNA-induced silencing complex overloading.
48. Castanotto D, Sakurai K, Lingeman R et al. Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res. 35, 5154-5164 (2007).
49. Boudreau RL, Martins I, Davidson BL. Artificial microRNAs as siRNA shuttles: improved safety as compared with shRNAs in vitro and in vivo. Mol. Ther. 17(1), 169-175 (2009).
50. Khan AA, Betel D, Miller ML, Sander C, Leslie CS, Marks DS. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat. Biotech. 27, 549-555 (2009).
51. Khodr CE, Sapru MK, Pedapati J et al. An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons. Brain Res. 1395, 94-107 (2011).
52. McBride JL, Boudreau RL, Harper SQ et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. PNAS 105(15), 5868-5873 (2008).
53. Martin JN, Wolken N, Brown T, Dauer WT, Ehrlich ME, Gonzalez-Alegre P. Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic design. Gene Ther. 18(7), 666-673 (2011).
54. Ehlert EM, Eggers R, Niclou SP, Verhaagen J. Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system. BMC Neurosci. 11, 20 (2010).
55. Kiang AS, Palfi A, Ader M et al. Toward a gene therapy for dominant disease: validation of an RNA interference-based mutation-independent approach. Mol. Ther. 12, 555-561 (2005).
56. Hong H, Zhang Y, Cai W. In vivo imaging of RNA interference. J. Nucl. Med. 51, 169-172 (2010).
57. Kim E, Park TG, Oh Y, Shim C. Assessment of siRNA pharmacokinetics using ELISA-based quantification. J. Cont. Rel. 143, 80-87 (2010).
58. Raymond CK, Roberts BS, Garrett-Engele P, Lim LP, Johnson JM. Simple, quantitative primer-extension PCR assay for direct monitoring of microRNAs and short-interfering RNAs. RNA 11, 1737-1744 (2005).
59. Liu WL, Stevenson M, Seymour LW, Fisher KD. Quantification of siRNA using competitive qPCR. Nucleic Acids Res. 37(1), e4 (2009).
60. Pei Y, Hancock PJ, Zhang H. Quantitative evaluation of siRNA delivery in vivo. RNA 16, 2253-2263 (2010). Describes a novel method for assessing siRNA uptake using immunoprecipitated RNA-induced silencing complexes.
61. Nitta T, Hata M, Gotoh S et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J. Cell. Biol. 210(1), 81-85 (2003).
62. Campbell M, Kiang AS, Kenna PF et al. RNAi-mediated reversible opening of the blood-brain barrier. J. Gene Med. 10(8), 930-947 (2008). Outlines the first report of RNAi-mediated blood-brain barrier modulation.
63. Tam LCS, Kiang AS, Campbell M et al. Prevention of autosomal dominant retinitis pigmentosa by systemic drug therapy targeting heat shock protein 90 (Hsp90). Hum. Mol. Gen. 19(22), 4421-4436 (2010).
64. Kennan A, Aherne A, Humphries P. Light in retinitis pigmentosa. Trends Genet. 21, 103-110 (2005).
65. Rossi JJ. Inducible and reversible breaching of the blood-brain barrier by RNAi. EMBO Mol. Med. 3(4), 186-188 (2011).
66. ClinicalTrials. Phase 2b study of ALN-RSV01 in lung transplant patients infected with Respiratory Syncytial Virus (RSV). http://clinicaltrials.gov/ct2/ show/NCT01065935
67. Alnylam Pharmaceuticals. Alnylam and Cubist announce complete data from Phase II study of ALN-RSV01 in lung transplant patients naturally infected with respiratory syncytial virus. http://phx.corporate-ir.net/preview/ phoenix.zhtml?c=148005&p=irolnewsArticle&ID=1308924&highlight=
68. ClinicalTrials. Prospective, randomized, multi-center, comparator study evaluating efficacy and safety of PF-04526355 versus laser in subjects with diabetic macular edema (DEGAS).http://clinicaltrials.gov/ct2/show/NCT00701181
69. ClinicalTrials. Phase II open label multicenter study for age related macular degeneration comparing an investigational drug PF-04526355 versus Lucentis in the treatment of subjects with choroidal neovascularization (MONET Study). http://clinicaltrials.gov/ct2/show/NCT00713518 NLM identifier: NCT00713518
70. Alnylam Pharmaceuticals. Programs and pipeline: hypercholesterolemia. http://alnylam.com/Programs-and-Pipeline/Alnylam-5x15/Hypercholestoralemia.php
71. ClinicalTrials.gov. http://clinicaltrials.gov